Related Experiment Video
Updated: Jul 7, 2026
10:58
Application of End-to-end Anastomosis in Robotic Central Pancreatectomy
Published on: June 2, 2018
Insulin for the world's poorest countries
1Royal Free and University College London School of Medicine, Whittington Hospital, UK. j.yudkin@ucl.ac.uk
Lancet (London, England)
|February 7, 2001
Summary
Type 1 diabetes is fatal in developing nations due to lack of insulin. A proposal suggests insulin manufacturers donate $3-5 million annually to save lives in the poorest countries.
Area of Science:
- Endocrinology and Metabolism
- Global Health
- Public Health Policy
Background:
- Type 1 diabetes (T1D) management is severely limited in developing countries due to intermittent insulin availability and cost.
- Ketoacidosis remains a significant cause of mortality from T1D in low-income regions, drastically reducing life expectancy.
- Highly Indebted Poor Countries (HIPCs) face substantial health program challenges, impacting access to essential medicines like insulin.
Purpose of the Study:
- To highlight the critical need for insulin access in HIPCs for Type 1 diabetes patients.
- To propose a sustainable solution for providing essential insulin therapy in resource-limited settings.
- To advocate for global health initiatives addressing T1D disparities.
Main Methods:
- Analysis of T1D incidence and prognosis in HIPCs compared to industrialized nations.
- Estimation of the global insulin quantity required to treat T1D patients in HIPCs.
- Development of a proposal for insulin donation by manufacturers.
Main Results:
- A small fraction (0.48%) of global insulin use could treat all T1D patients in HIPCs.
- The estimated annual cost for sufficient insulin donation is US$3-5 million.
- The proposed initiative includes distribution and education for T1D patients.
Conclusions:
- No Type 1 diabetes patient in the world's poorest countries should die due to unaffordability of insulin.
- A collaborative effort between insulin manufacturers and global health organizations can bridge the insulin gap.
- Implementing this donation program can significantly improve T1D patient outcomes in HIPCs.
Related Concept Videos
01:18Metabolic States of the Body: The Postabsorptive State
The postabsorptive state usually starts about four hours after a meal and lasts until the next meal is eaten. During this time, the digestive system stops absorbing nutrients, and the body uses stored energy reserves to maintain stable blood glucose levels.
Initially, glycogen stored in the liver is broken down to release glucose into the bloodstream, while glycogen in the muscles is broken down to supply glucose for energy directly within the muscle cells. As glycogen stores diminish,...
Initially, glycogen stored in the liver is broken down to release glucose into the bloodstream, while glycogen in the muscles is broken down to supply glucose for energy directly within the muscle cells. As glycogen stores diminish,...
01:24Metabolic States of the Body: Fasting and Starvation
During the initial hours of fasting, the body uses up its glycogen stores as an energy source. Once these glycogen reserves are depleted, the body begins breaking down stored triglycerides and structural proteins. During this stage, glycerol becomes a key substrate for gluconeogenesis, while free fatty acids undergo beta-oxidation to provide energy for tissues, such as skeletal muscle. In the fasting state, the body spares protein breakdown as much as possible to conserve muscle and structural...
01:15Enteral Nutrition II: Nasointestinal and Gastrostomy Feeding
Enteral nutrition encompasses various methods of delivering nutrition directly to the gastrointestinal (GI) tract, bypassing traditional oral intake. It is particularly beneficial for patients who cannot eat by mouth but have a functioning digestive system. Key methods include nasointestinal feeding, gastrostomy, and jejunostomy, each suited to different clinical scenarios based on the patient's needs and condition.
Nasointestinal Feeding
Nasointestinal feeding involves placing a tube through...
Nasointestinal Feeding
Nasointestinal feeding involves placing a tube through...
01:15Hypoglycemia and Glucagon
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
01:30Production of Pharmaceuticals
Industrial insulin production uses genetically engineered E. coli expressing a proinsulin gene controlled by a tryptophan promoter and containing a methionine linker for later cleavage. The cells also carry ampicillin resistance for selective growth. Seed cultures are stored at −80 °C and production begins by thawing a small amount to inoculate starter cultures, which are progressively scaled to a 50,000-L bioreactor. In the bioreactor, E. coli grow in nutrient-rich media under sterile, tightly...
01:25Hepatitis
Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver. The...